The number of shares and votes in Q-linea AB (publ) (the “Company”) increased during November 2025 as a result of: (i) the rights issue resolved by the board of directors on September 18, 2025, and approved by the extraordinary general meeting on October 21, 2025, and (ii) the directed issue of 16,800 shares to a guarantor in connection with the rights issue, resolved by the board of directors on November 17, 2025, pursuant to authorization from the general meeting.

As of November 28, 2025, the total number of shares in the Company amounts to 18,949,081 shares (previously 6,436,873 shares), each carrying one vote. All shares are common shares. The share capital amounts to SEK 1,894,908.10 (previously SEK 643,687.30). As of November 28, 2025, Q-linea AB holds 329 of its own shares.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

This information is information that Q-linea is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-11-28 11:00 CET.

Attachments

New number of shares and votes in Q-linea AB (publ)

Läs mer på MFN